Worse outcomes after conversion of thoracoscopic lobectomy for lung cancer.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
08 04 2021
Historique:
received: 24 04 2020
revised: 08 10 2020
accepted: 13 10 2020
pubmed: 23 11 2020
medline: 24 7 2021
entrez: 22 11 2020
Statut: ppublish

Résumé

Conversion of thoracoscopic lobectomy for lung cancer to thoracotomy can adversely affect short-term outcomes, but the impact on long-term outcomes is unknown. This study aimed to identify the risk factors for conversion and to determine the influence of conversion on the outcomes of lung cancer treatment. This retrospective study included 1002 consecutive patients with lung cancer who underwent thoracoscopic lobectomy between 7 June 1999 and 17 July 2018. The groups of patients with and without conversion were compared in terms of possible risk factors and the short- and long-term outcomes. The survival of patients was analysed by the Kaplan-Meier method. Conversion was done in 105 patients (10.5%). On multivariable logistic regression analysis, the independent risk factors for conversion were pleural adhesions (P < 0.001) and mediastinal lymph node metastases (P < 0.001). Compared with the non-conversion group, the conversion group had longer chest drainage time (4 vs 3 days, P < 0.001) and hospital stay (8 vs 6 days, P < 0.001); more frequent complications (38.1% vs 27.1%, P = 0.018), including red blood cell transfusion (10.5% vs 2%, P < 0.001) and supraventricular arrhythmia (13.3% vs 7.5%, P = 0.037); and lower 5-year survival rate in patients with stage I lung cancer (70% vs 87%, P = 0.014). Conversion did not increase in-hospital mortality. Pleural adhesions and lymph node metastases increased the probability of conversion to thoracotomy. Conversion adversely affected the short-term outcomes of thoracoscopic lobectomy. Long-term outcomes of treatment of non-small-cell lung cancer could be worse in patients after conversion, but definitive conclusions cannot be made in this regard because of the absence of control of selection bias.

Identifiants

pubmed: 33221893
pii: 5998429
doi: 10.1093/icvts/ivaa274
pmc: PMC8906676
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-363

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Références

Lancet Oncol. 2016 Jun;17(6):836-844
pubmed: 27160473
Interact Cardiovasc Thorac Surg. 2011 Jun;12(6):962-4
pubmed: 21388988
Surg Endosc. 2008 Mar;22(3):640-5
pubmed: 17623249
Eur J Cardiothorac Surg. 2018 Sep 1;54(3):547-553
pubmed: 29547899
J Thorac Cardiovasc Surg. 2010 Apr;139(4):976-81; discussion 981-3
pubmed: 20172539
Eur J Cardiothorac Surg. 2016 Feb;49(2):602-9
pubmed: 25913824
Ann Thorac Surg. 2001 Aug;72(2):362-5
pubmed: 11515867
J Thorac Cardiovasc Surg. 2015 Jan;149(1):55-61, 62.e1
pubmed: 25439768
Surg Endosc. 2016 Jun;30(6):2415-21
pubmed: 26335073
J Thorac Cardiovasc Surg. 2009 Jul;138(1):11-8
pubmed: 19577048
Thorac Cancer. 2015 Nov;6(6):704-8
pubmed: 26557907
J Thorac Cardiovasc Surg. 2018 Mar;155(3):1254-1264.e1
pubmed: 29221736
Ann Thorac Surg. 2017 Jul;104(1):329-335
pubmed: 28587738
J Thorac Dis. 2017 Aug;9(8):2427-2436
pubmed: 28932548
J Thorac Cardiovasc Surg. 2013 Feb;145(2):514-20; discussion 520-1
pubmed: 23177123
Ann Thorac Surg. 2015 Sep;100(3):968-73
pubmed: 26188973
Eur J Cardiothorac Surg. 2014 May;45(5):787-98
pubmed: 24578407
World J Surg. 2011 Mar;35(3):590-5
pubmed: 21181470
J Thorac Cardiovasc Surg. 2013 Jun;145(6):1512-8
pubmed: 22698554
Chest. 2013 May;143(5 Suppl):e314S-e340S
pubmed: 23649445
Surg Laparosc Endosc. 1992 Sep;2(3):244-7
pubmed: 1341539
Ann R Coll Surg Engl. 2017 Feb;99(2):129-133
pubmed: 27502339
Kardiochir Torakochirurgia Pol. 2018 Jun;15(2):65-71
pubmed: 30069185

Auteurs

Piotr Gabryel (P)

Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Cezary Piwkowski (C)

Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Mariusz Kasprzyk (M)

Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Paweł Zieliński (P)

Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Magdalena Roszak (M)

Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland.

Wojciech Dyszkiewicz (W)

Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH